Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Scope of Available Evidence

The review rests on three 2026 preprints (no peer-reviewed journal publications or citation metrics were retrievable; an OpenAlex lookup returned a rate-limit error, so citation counts, h-index, and career timeline remain unknown). All three works are consortial or team-driven, so McDonough's individual contribution cannot be isolated from the records.

Scientific Portfolio

1. Data infrastructure: The HuBMAP FAIRness framework paper (48 references) details metadata schemas, a provenance model covering six stages and 52 assay types, and open-source tooling, with NIH FAIRness assessments reporting high performance HuBMAP metadata standards paper. 2. Dataset engineering: Prostate-TriMod integrates 717 cores from 212 patients, 12 markers, ~1.28 million annotated cells, and multiscale tiling; reported cross-scale concordance exceeds 95% and immune infiltration associates with Grade Group/BCR (p < 2e-18) Prostate-TriMod cohort details. 3. AI prognostication: A five-protein cancer stem-cell signature (GLUT1, FLIP up; BAK, BAX, MLKL, CDX2 down) trained in a DNN over 466 stage III CRC patients (120 early recurrence, 346 late/no) achieved independent validation in the RCSI cohort after repeated 8-fold cross-validation CRC DNN biomarker validation.

Critical Assessment

Strengths: Consistent theme of rigorous single-cell spatial biology plus AI; large, well-characterized cohorts; explicit falsification criteria and honest limitation statements across all three papers; multi-cohort design with independent validation in the CRC study. Weaknesses/blindspots: (a) all three are preprints with zero incoming citations, so community validation is absent; (b) reproducibility is the weakest dimension — the CRC paper provides no data accessions, and Prostate-TriMod data are restricted during peer review; (c) single-institution (Stanford) prostate cohort limits generalization, acknowledged by the authors Prostate-TriMod limitations; (d) TMA sampling (2–3 cores/patient) may underrepresent intratumoral heterogeneity CRC study blindspots. What would change this assessment: peer-reviewed acceptance, post-publication citations, external multi-center replication of both signatures, and full data/code release would materially raise confidence; failure of the signatures in external cohorts would falsify the central prognostic claims. Confidence in this review is moderate — it reflects only three preprints with unverifiable authorship roles.

 BGPT Author Review

Scientific Quality

Three coherent 2026 preprints show solid methodological breadth (multiplexed imaging, DNNs, FAIR infrastructure) with independent validation in one study, but all are unreviewed, uncited, team-authored, and none demonstrates a verifiable individual contribution; mid-level established scientist profile with strong collaborative promise but unproven standalone track record.

Communication Quality

Papers include explicit falsification criteria, structured limitations, and clear one-sentence summaries — above-average transparency and clarity. Deductions because rule-based captioning and complex consortium schemas reduce accessibility for non-specialist readers.

Author Novelty

Tri-modal histology with multiscale rule-based captions and a stem-cell spatial-proteomics DNN signature are creative within computational pathology, though both build on established tools (CONCH, Cell DIVE, TMAs); incremental-plus rather than paradigm-shifting.

Scientific Rigor

Repeated cross-validation, independent cohort validation, and explicit falsification criteria are rigorous practices. However, no public data accessions for the CRC study, restricted dataset release for Prostate-TriMod, withheld preprocessing code, and single-center sampling reduce verifiable rigor.